• 原料直供
• 试剂商城
• 直接询价

分类

• Pharmaceuticals
• {SNA} Antagonists, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Biochemicals and Reagents, Cell Biology, Cell Signaling and Neuroscience, Dopaminargics - Antagonists, Dopaminergics, GPCR Modulators, GPCR Proteins, Modulators and Antibodies, L, Membrane Protein Biology Tools, Neuroscience, Neurotransmission, Neurotransmitters, Proteins and Derivatives, Watson
• {SNA} Antagonists, Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Dopaminargics - Antagonists, Dopaminergics, GPCR Modulators, GPCR Prot
• Intermediates & Fine Chemicals,

产品应用

• A D2/D4-Dopamine receptor antagonist. A serotonergic receptor antagonist. A dibenzoxazepine antipsychotic agent.

相关文献及参考

• [2]. Labuzek K, et al. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol. 2005 Jan;15(1):23-30.
• [3]. Lee T, et al. Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res. 1984 Aug;12(4):277-85.
• [4]. Kalkman HO, et al. Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):361-4.
• Fiorella, D., et al.: Psychopharmacology, 121, 347 (1995),
• Shen, Y., et al.: J. Biol. Chem., 268, 18200 (1993),
• [1]. Singh AN, et al. A neurochemical basis fo
• [1]. Singh AN, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci. 1996 Jan;21(1):29-35.

安全信息

TYPE OF TEST            : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE/DURATION           : 30 mg/kg
TOXIC EFFECTS :
   Behavioral - convulsions or effect on seizure threshold
   Behavioral - coma
   Lungs, Thorax, or Respiration - chronic pulmonary edema
REFERENCE :
   CTOXAO Clinical Toxicology.  (New York, NY)  V.1-18, 1968-81.  For publisher
   information, see JTCTDW.  Volume(issue)/page/year: 14,181,1979

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE/DURATION           : 6 mg/kg/2D-I
TOXIC EFFECTS :
   Behavioral - toxic psychosis
REFERENCE :
   JCLPDE Journal of Clinical Psychiatry.  (Physicians Postgraduate Press,
   Inc., POB 240008, Memphis, TN 38124)  V.39-    1978-
   Volume(issue)/page/year: 44,37,1983

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE/DURATION           : 27 mg/kg/9D-I
TOXIC EFFECTS :
   Endocrine - hyperglycemia
REFERENCE :
   JCLPDE Journal of Clinical Psychiatry.  (Physicians Postgraduate Press,
   Inc., POB 240008, Memphis, TN 38124)  V.39-    1978-
   Volume(issue)/page/year: 44,347,1983